5,820
Participants
Start Date
September 30, 2009
Primary Completion Date
December 31, 2012
Study Completion Date
December 31, 2013
Sulphadoxine-pyrimethamine
SP oral administration (500mg sulphadoxine and 25mg pyrimethamine) as IPTp at the 1st and 2nd Antenatal Clinic visit
Mefloquine (full dose)
MQ oral administration (15 mg/Kg) on 1 day at the 1st and 2nd Antenatal Clinic visit as IPTp
Mefloquine (split dose)
MQ oral administration (15 mg/kg) split dose over 2 days at the 1st and 2nd ANC visit as IPTp
placebo
MQ-placebo oral administration at the 1st, 2nd and 3rd Antenatal Clinic visit as IPTp
mefloquine
MQ oral administration (15 mg/Kg) at the 1st and 2nd Antenatal Clinic visit as IPTp
Faculté des Sciences de la Santé (FSS), Université d'Abomey Calavi, Allada
Medical Rsearch Unit (MRU), Albert Schweitzer Hospital, Lambaréné
Kenya Medical Research Institute (KEMRI)/ CDC, Kisumu
Centro de Investigaçao em Saúde da Manhiça (CISM), Manhiça
Ifakara Health Institute (IHI), Dodoma
Collaborators (1)
Barcelona Centre for International Health Research
OTHER
Institute of Tropical Medicine, University of Tuebingen
OTHER
Institut de Recherche pour le Developpement
OTHER_GOV
Université d'Abomey-Calavi
OTHER
Albert Schweitzer Hospital
OTHER
Kenya Medical Research Institute
OTHER
Ifakara Health Institute
OTHER
Centro de Investigacao em Saude de Manhica
OTHER
Vienna School of Clinical Research (VSCR), Austria.
UNKNOWN
Centers for Disease Control and Prevention
FED
Malaria in Pregnancy Consortium
OTHER
Hospital Clinic of Barcelona
OTHER